Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma C Cesana, C Klersy, L Barbarano, AM Nosari, M Crugnola, E Pungolino, ... Journal of Clinical Oncology 20 (6), 1625-1634, 2002 | 344 | 2002 |
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients N Giuliani, F Morandi, S Tagliaferri, M Lazzaretti, S Bonomini, M Crugnola, ... Blood, The Journal of the American Society of Hematology 110 (1), 334-338, 2007 | 304 | 2007 |
Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis F Palandri, M Breccia, M Bonifacio, N Polverelli, EM Elli, G Benevolo, ... Cancer 126 (6), 1243-1252, 2020 | 122 | 2020 |
Survival of elderly patients with acute myeloid leukemia A Pulsoni, L Pagano, R Latagliata, M Casini, R Cerri, M Crugnola, ... haematologica 89 (3), 296-302, 2004 | 108 | 2004 |
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival N Giuliani, S Bonomini, P Romagnani, M Lazzaretti, F Morandi, S Colla, ... Haematologica 91 (11), 1489-1497, 2006 | 102 | 2006 |
Differences among young adults, adults and elderly chronic myeloid leukemia patients F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ... Annals of Oncology 26 (1), 185-192, 2015 | 101 | 2015 |
Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease L Arcaini, M Paulli, S Burcheri, A Rossi, M Spina, F Passamonti, M Lucioni, ... British journal of haematology 136 (2), 301-304, 2007 | 97 | 2007 |
Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients S Colla, F Morandi, M Lazzaretti, R Rizzato, P Lunghi, S Bonomini, ... Leukemia 19 (12), 2166-2176, 2005 | 96 | 2005 |
Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission M Bocchia, A Sicuranza, E Abruzzese, A Iurlo, S Sirianni, A Gozzini, ... Frontiers in Oncology 8, 194, 2018 | 94 | 2018 |
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis F Palandri, R Latagliata, N Polverelli, A Tieghi, M Crugnola, B Martino, ... Leukemia 29 (6), 1344-1349, 2015 | 91 | 2015 |
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP M Baccarani, E Abruzzese, V Accurso, F Albano, M Annunziata, S Barulli, ... Blood advances 3 (24), 4280-4290, 2019 | 81 | 2019 |
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia R Latagliata, M Breccia, C Fava, F Stagno, M Tiribelli, L Luciano, ... Hematological oncology 31 (2), 103-109, 2013 | 81 | 2013 |
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease K Todoerti, G Lisignoli, P Storti, L Agnelli, F Novara, C Manferdini, ... Experimental hematology 38 (2), 141-153, 2010 | 77 | 2010 |
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis F Palandri, GA Palumbo, M Bonifacio, M Tiribelli, G Benevolo, B Martino, ... Oncotarget 8 (45), 79073, 2017 | 75 | 2017 |
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice C Fava, G Rege-Cambrin, I Dogliotti, M Cerrano, P Berchialla, M Dragani, ... haematologica 104 (8), 1589, 2019 | 73 | 2019 |
Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas S Monfardini, SML Aversa, V Zoli, L Salvagno, A Bianco, R Bordonaro, ... Annals of oncology 16 (8), 1352-1358, 2005 | 64 | 2005 |
The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia … F Palandri, F Castagnetti, I Iacobucci, G Martinelli, M Amabile, G Gugliotta, ... haematologica 95 (8), 1415, 2010 | 62 | 2010 |
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients S Soverini, C De Benedittis, KM Polakova, J Linhartova, F Castagnetti, ... Oncotarget 7 (16), 21982, 2016 | 61 | 2016 |
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients M Breccia, F Efficace, S Sica, E Abruzzese, M Cedrone, D Turri, M Gobbi, ... Leukemia research 39 (10), 1055-1059, 2015 | 60 | 2015 |
Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG A Olivieri, G Santini, C Patti, T Chisesi, C De Souza, A Rubagotti, ... Annals of oncology 16 (12), 1941-1948, 2005 | 55 | 2005 |